HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Press releases
June 8, 2022
François Fournier as new CEO
Javené, June 8th, 2022 –
An experienced healthcare executive and expert in HTL’s therapeutic areas, in particular dermatology and medical aesthetics, François Fournier brings more than 20 years’ experience in corporate strategy, business execution, and international leadership.
Prior to joining HTL, François Fournier, of French and American nationality, worked in many
countries and several continents in different management positions at pharmaceutical companies,
including most recently at Virbac (as president and CEO of Virbac North America based in Dallas) and previously at Smith & Nephew and Galderma.
Read more below
To see our most recent news,
follow us on LinkedIn
Read more
news from us
-
Articles October 29, 2025HTL Inside Webinar: a success that boosts our visibility in Asia
On October 28, 2025, HTL Biotechnology hosted its first-ever webinar, “Shaping the Future of Aesthetic Medicine with Premium Biopolymers,” a key initiative to strengthen our presence in Asia and promote the “Feel the Difference with HTL Inside” positioning among major players in aesthetic medicine.
-
Articles October 9, 2025HTL Biotechnology rallies for Pink October 2025
This October, HTL Biotechnology turned pink to support breast cancer prevention.
-
Articles September 19, 2025HTL Biotechnology wins the Responsible Care 2025 Award
HTL Biotechnology is the winner of the Responsible Care West Atlantic Trophy in the ‘Energy – Climate’ category for its project to reduce carbon emissions from distillation systems.